Louis Cohen is a Gastroenterology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5 E 98th St
New York, NY 100296501
Telephone
212-241-4299Registry record last updated 22 Feb 2019.
Clinical trials
- Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Sponsor: Washington University School of Medicine
- Autologous Stem Cell Transplant for Crohn's Disease
Sponsor: Aaron Etra
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- Exact Sciences CorporationProgram year20252 payments
- Janssen Biotech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.1%Proton pump inhibitor22.2%Omeprazole68%Pantoprazole Sodium32%Part D<11 patientsAntidiarrheal11.1%Diphenoxylate-Atropine100%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
28.1%TNF inhibitor16.4%Humira(Cf) Pen100%Part D<11 patientsInterleukin-12 Antagonist11.7%Stelara100%Part D<11 patientsNervous system
15.8%Benzodiazepine15.8%Clonazepam52%Alprazolam48%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- Understanding hematopoietic stem cell dysfunction in refractory Crohn's disease
Icahn School of Medicine at Mount Sinai
FY2026$645,617R01DK143239 - Characterization of lectins to understand human microbiome functions and develop live biotherapeutics
Icahn School of Medicine at Mount Sinai
FY2026$371,800R01DK135675 - Understanding hematopoietic stem cell dysfunction in refractory Crohn's disease
Icahn School of Medicine at Mount Sinai
FY2025$645,617R01DK143239
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”